Luvero Daniela, Angioli Roberto, Notaro Erika, Plotti Francesco, Terranova Corrado, Angioli Anna Maria, Festa Asia, Stermasi Andi, Manco Serena, Diserio Miriana, Montera Roberto
Department of Gynecology, Fondazione Policlinico Universitario Campus Bio Medico, Via Alvaro del Portillo 200, 00128 Roma, Italy.
Research Unit of Gynecology, Department of Medicine and Surgery, Università Campus Bio Medico, Via Alvaro del Portillo 21, 00128 Roma, Italy.
Diagnostics (Basel). 2024 Nov 16;14(22):2577. doi: 10.3390/diagnostics14222577.
Serous tubal intraepithelial carcinoma (STIC) is an early-stage cancerous lesion found in the fallopian tubes, often at the fimbrial end. It is strongly associated with high-grade serous carcinoma (HGSC), a highly aggressive type of ovarian cancer. STIC is considered a precursor to many HGSC cases, originating in the fallopian tubes. Its development is frequently linked to mutations in the TP53 gene, leading to the formation of a p53 signature, an early abnormality that may progress to HGSC. This signature is more common in BRCA mutation carriers, explaining the higher incidence of STIC in this group. The aim of this review is to evaluate the literature on the incidence of serous tubal intraepithelial carcinoma in patients (both BRCA-positive and BRCA-negative) undergoing preventive salpingo-oophorectomy, analysing the available data and identifying associations between specific characteristics and the onset of STIC.
A comprehensive review of the literature from 2016 to 2023 was conducted using PubMed, focusing on studies analysing the incidence of STIC in BRCA-positive patients undergoing preventive salpingo-oophorectomy. Data on patient characteristics, interventions, outcomes, and incidence of STIC were extracted and analysed.
Nine international studies were included in the review, reporting varying incidences of STIC among patients undergoing salpingo-oophorectomy. The overall incidence of STIC in all the women included in the studies was 7.31%, while that in the BRCA-mutated women was approximately 6.08%. Notably, the presence of the TP53 signature was significantly associated with the occurrence of STIC.
The etiopathogenesis of STIC involves complex interactions between genetic, environmental, and molecular factors. Further research is needed to fully understand its mechanisms and identify additional risk factors beyond BRCA mutations. Establishing a national database of STIC cases could facilitate future research and improve patient outcomes.
浆液性输卵管上皮内癌(STIC)是在输卵管中发现的早期癌前病变,通常位于输卵管伞端。它与高级别浆液性癌(HGSC)密切相关,HGSC是一种侵袭性很强的卵巢癌类型。STIC被认为是许多HGSC病例的起源,起源于输卵管。其发展通常与TP53基因突变有关,导致p53特征的形成,这是一种可能进展为HGSC的早期异常。这种特征在BRCA突变携带者中更常见,这解释了该群体中STIC的发病率较高。本综述的目的是评估接受预防性输卵管卵巢切除术的患者(包括BRCA阳性和BRCA阴性)中浆液性输卵管上皮内癌的发病率,分析现有数据并确定特定特征与STIC发病之间的关联。
使用PubMed对2016年至2023年的文献进行了全面综述,重点关注分析接受预防性输卵管卵巢切除术的BRCA阳性患者中STIC发病率的研究。提取并分析了患者特征、干预措施、结局和STIC发病率的数据。
该综述纳入了9项国际研究,报告了接受输卵管卵巢切除术的患者中STIC的发病率各不相同。纳入研究的所有女性中STIC的总体发病率为7.31%,而BRCA突变女性中的发病率约为6.08%。值得注意的是,TP53特征的存在与STIC的发生显著相关。
STIC的发病机制涉及遗传、环境和分子因素之间的复杂相互作用。需要进一步研究以充分了解其机制,并确定除BRCA突变之外的其他风险因素。建立STIC病例的国家数据库有助于未来的研究并改善患者结局。